Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2011. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs). It details the granting of new share-based awards on February 24, 2011, and the vesting or lapsing of awards from the 2008 Share Option Plan and Performance Share Plan on February 25, 2011.
Key Financial Metrics and Compensation Details
The filing does not report consolidated revenue, profit, cash flow, or debt metrics for the company. Instead, it provides specific financial thresholds used for executive compensation performance measures:
- Adjusted Free Cash Flow Thresholds: Vesting for this metric begins at £16.15 billion (25% vesting), reaches 50% at £16.65 billion, 75% at £18.32 billion, and maximum vesting at £19.15 billion.
- Share Prices at Grant: Awards were calculated using an Ordinary share price of £11.78 and an ADS price of US$38.13 (February 24, 2011) for the Performance Share Plan, and £11.80/US$38.22 for the Deferred Annual Bonus Plan.
Material Changes and Performance Outcomes
The filing reports significant changes in executive equity holdings based on the conclusion of the 2008-2010 performance period:
- 2008 Share Option Plan (SOP): Awards subject to performance conditions for Executive Directors and CET members lapsed entirely because the performance condition was not met. Conversely, grants to senior executives who were not subject to performance conditions became fully exercisable.
- 2008 Performance Share Plan (PSP):
- Executive Directors/CET: Awards were wholly dependent on Total Shareholder Return (TSR). GSK ranked at the median of the comparator group, resulting in 35% of the awards vesting and 65% lapsing.
- Senior Executives (CET appointees): Awards were split between TSR (50%) and EPS (50%). The EPS condition was not met (50% lapsed). The TSR portion vested at 35%, resulting in a total vesting of 17.5% of the original award.
Guidance, Outlook, and New Awards
New awards granted on February 24, 2011, under the 2009 Performance Share Plan and 2009 Deferred Annual Bonus Plan are tied to a three-year performance period (January 1, 2011, to December 31, 2013). The awards are based on four equally weighted measures:
- Total Shareholder Return (TSR): Relative performance against ten global pharmaceutical peers. Vesting ranges from 0% (below median) to 100% (top 3rd place).
- Adjusted Free Cash Flow: Based on operating profit adjusted for material factors. Specific monetary thresholds are set for vesting levels.
- R&D New Product Measure: Based on New Product Sales (NPS) for products launched within a five-year window. Specific targets are withheld due to commercial sensitivity.
- Business Diversification: Focuses on revenue targets for Vaccines, Dermatology, Consumer Healthcare, Emerging Markets, and Japan. Specific targets are withheld due to commercial sensitivity.
The filing notes that specific targets for R&D and Business Diversification will be disclosed at the end of the performance period.
Key Facts for Investor Verification
- Verify the company's actual Adjusted Free Cash Flow performance against the £16.15 billion to £19.15 billion thresholds set for the 2011-2013 period.
- Monitor GSK's TSR ranking relative to the specified comparator group (Abbott, AstraZeneca, BMS, Eli Lilly, J&J, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis) to determine future vesting.
- Note that 2008 performance targets for EPS were not met, leading to significant lapses in executive equity awards.
- Confirm future disclosures regarding the specific numerical targets for R&D New Product Sales and Business Diversification revenue, which are currently undisclosed.